Oxford Nanopore Technologies plc
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Francis Albert Luc Van Parys
- Full Time Employees
- 1,403
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Gosling Building Oxford OXF United Kingdom OX4 4DQ
- IPO Date
- Oct 15, 2021
- Website
- nanoporetech.com
- Similar Companies
- Business
- Oxford Nanopore Technologies plc (ONT:LN) develops and commercializes nanopore-based sequencing platforms for real-time, scalable analysis of DNA, RNA, proteins and small molecules; its core products include the portable MinION and Flongle devices for on-demand small-scale sequencing, the benchtop GridION X5 supporting up to five MinION Flow Cells for up to 100 gigabases per run, the high-throughput PromethION and compact PromethION 2 systems delivering over 10 terabases in population-scale projects, the VolTRAX automated sample preparation instrument, library preparation kits such as 10-minute protocols, and EPI2ME cloud-based analysis workflows. Founded in 2005 as a spin-out from the University of Oxford and headquartered at the Oxford Science Park in Oxford, UK, the company operates satellite offices in Cambridge and multiple US, Asian and European locations, selling to over 120 countries across scientific research, healthcare, agriculture, environmental monitoring, infectious disease detection, cancer research, metagenomics, epigenetics and in vitro diagnostics. In October 2025, Oxford Nanopore expanded its collaboration with Bio-Techne through 2032 to accelerate development and commercialization of a broader genetics portfolio on its platform, building on the March 2025 launch of Bio-Techne's AmplideX Nanopore Carrier Plus Kit for heritable disorder screening; the company also reported H1 2025 revenue of £105.6 million, up 26% year-on-year, reflecting strong demand, and received a £50 million investment from Novo Holdings in 2024 to support biopharma applications.
Oxford Nanopore shares slide 16% after first-half sales miss expectations
Leading banks back Oxford Nanopore after London Calling showcases maturing platform
Oxford Nanopore and A.D.A.M. Innovations Announce International Collaboration to Accelerate Advanced Genomic Medicine in Japan
Oxford Nanopore Technologies plc (ONTTF) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
ViruSure Launches First GMP-Validated Viral Safety Test Based on Oxford Nanopore Sequencing
Citi keeps 'buy' rating on Oxford Nanopore as profitability target holds despite revenue miss
Oxford Nanopore Technologies plc (ONTTF) Q4 2025 Earnings Call Transcript
Oxford Nanopore Technologies plc (ONTTF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Oxford Nanopore rises on strong 2025 revenue growth
Oxford Nanopore Receives Regulatory Approval for its First Diagnostic Device in the UK and Europe
Oxford Nanopore Technologies plc (ONTTF) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Oxford Nanopore Announces PromethION Plus Flow Cell and Human Genetics Updates at ASHG 2025
Bio-Techne and Oxford Nanopore Technologies Expand Agreement to Accelerate Development of Genetics Portfolio Through 2032
Oxford Nanopore Technologies plc (ONTTF) Q2 2025 Earnings Call Transcript
Oxford Nanopore falls despite underlying loss beating expectations
ViruSure launches pioneering first-in-class viral contamination test for biopharmaceuticals using Oxford Nanopore technology
Oxford Nanopore price target raised to 240 GBp from 180 GBp at Citi
Oxford Nanopore jumps as US bank hikes forecasts and price target
Oxford Nanopore leaps 20% after stronger first half trading
Breakthrough algorithm enables partially phased, near telomere-to-telomere assembly using standard Oxford Nanopore Simplex reads